文献速递卫生政策与健康促进传染病防控与疫情报告

COVID-19治疗药物获取的种族和民族差异——美国,2020年3月至2021年8月

Racial and Ethnic Disparities in Receipt of Medications for Treatment of COVID-19 - United States, March 2020-August 2021.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2022-01-21

利用PCORnet 41个美国医疗系统的电子健康记录,分析805,276例SARS-CoV-2阳性患者和120,204例住院患者中COVID-19治疗药物的种族和民族差异。单克隆抗体总体使用率低,西班牙裔患者比非西班牙裔患者少58%,黑人、亚裔和其他种族患者比白人患者分别少22%、48%和47%。住院患者中差异较小且方向不同。

要点

  • 所有种族和民族组单克隆抗体月均使用率≤4%。
  • 西班牙裔患者接受单克隆抗体比非西班牙裔患者少58%。
  • 黑人、亚裔和其他种族患者接受单克隆抗体比白人患者分别少22%、48%和47%。

核心结论

  • 单克隆抗体使用率总体低,且存在种族和民族差异;住院药物差异较小且方向不同。
  • 公平获取门诊治疗和实施预防措施对减少COVID-19严重结局差异至关重要。

研究设计与样本

  • 使用PCORnet 41个美国医疗系统的COVID-19患者电子健康记录数据。
  • 分析805,276例SARS-CoV-2检测阳性患者中单克隆抗体治疗接受情况。
  • 分析120,204例SARS-CoV-2检测阳性住院患者中地塞米松和瑞德西韦治疗接受情况。

主要发现

  • 所有种族和民族组单克隆抗体月均使用率≤4%。
  • 2020年11月至2021年8月,西班牙裔患者接受单克隆抗体比非西班牙裔患者少58%。
  • 黑人、亚裔和其他种族患者接受单克隆抗体比白人患者分别少22%、48%和47%。
  • 西班牙裔住院患者接受地塞米松比非西班牙裔住院患者少6%。
  • 黑人住院患者接受瑞德西韦比白人住院患者多9%。

临床怎么用

  • 疫苗和预防措施是预防感染的最佳防御。
  • 暴露后或感染后使用COVID-19药物可降低发病率和死亡率并减轻医院压力,但不能替代COVID-19疫苗接种。
  • 以社区特定需求为中心的公共卫生政策和规划可促进健康公平。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The COVID-19 pandemic has magnified longstanding health care and social inequities, resulting in disproportionately high COVID-19-associated illness and death among members of racial and ethnic minority groups (1). Equitable use of effective medications (2) could reduce disparities in these severe outcomes (3). Monoclonal antibody (mAb) therapies against SARS-CoV-2, the virus that causes COVID-19, initially received Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA) in November 2020. mAbs are typically administered in an outpatient setting via intravenous infusion or subcutaneous injection and can prevent progression of COVID-19 if given after a positive SARS-CoV-2 test result or for postexposure prophylaxis in patients at high risk for severe illness.† Dexamethasone, a commonly used steroid, and remdesivir, an antiviral drug that received EUA from FDA in May 2020, are used in inpatient settings and help prevent COVID-19 progression§ (2). No large-scale studies have yet examined the use of mAb by race and ethnicity. Using COVID-19 patient electronic health record data from 41 U.S. health care systems that participated in the PCORnet, the National Patient-Centered Clinical Research Network,¶ this study assessed receipt of medications for COVID-19 treatment by race (White, Black, Asian, and Other races [including American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, and multiple or Other races]) and ethnicity (Hispanic or non-Hispanic). Relative disparities in mAb** treatment among all patients†† (805,276) with a positive SARS-CoV-2 test result and in dexamethasone and remdesivir treatment among inpatients§§ (120,204) with a positive SARS-CoV-2 test result were calculated. Among all patients with positive SARS-CoV-2 test results, the overall use of mAb was infrequent, with mean monthly use at 4% or less for all racial and ethnic groups. Hispanic patients received mAb 58% less often than did non-Hispanic patients, and Black, Asian, or Other race patients received mAb 22%, 48%, and 47% less often, respectively, than did White patients during November 2020-August 2021. Among inpatients, disparities were different and of lesser magnitude: Hispanic inpatients received dexamethasone 6% less often than did non-Hispanic inpatients, and Black inpatients received remdesivir 9% more often than did White inpatients. Vaccines and preventive measures are the best defense against infection; use of COVID-19 medications postexposure or postinfection can reduce morbidity and mortality and relieve strain on hospitals but are not a substitute for COVID-19 vaccination. Public health policies and programs centered around the specific needs of communities can promote health equity (4). Equitable receipt of outpatient treatments, such as mAb and antiviral medications, and implementation of prevention practices are essential to reducing existing racial and ethnic inequities in severe COVID-19-associated illness and death.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Wiltz JL, Feehan AK, Molinari NM, et al. Racial and Ethnic Disparities in Receipt of Medications for Treatment of COVID-19 - United States, March 2020-August 2021. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35051133. doi:10.15585/mmwr.mm7103e1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。